¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"persistent light reaction"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • reversal reaction
    ¿ªÀü¹ÝÀÀ
  • reverse transcriptase polymerase chain reaction
    ¿ªÀü»çÈ¿¼ÒÁßÇÕÈ¿¼Ò¿¬¼â¹ÝÀÀ
  • reversible reaction
    °¡¿ª¹ÝÀÀ
  • righting reaction
    ¹Ù·ÎÀâ±â¹ÝÀÀ
  • somatization reaction
    ½Åüȭ¹ÝÀÀ
  • specific capsular reaction
    ƯÀÌÇǸ·¹ÝÀÀ
  • static reaction
    Á¤Àû¹ÝÀÀ, ÆòÇü¹ÝÀÀ
  • stinging reaction
    µû°¡¿ò¹ÝÀÀ
  • stoichiometric reaction
    È­Çз®¹ÝÀÀ
  • stress reaction
    ½ºÆ®·¹½º¹ÝÀÀ
  • subcutaneous reaction
    ÇǺιعÝÀÀ, ÇÇÇϹÝÀÀ
  • successive reaction
    ¿¬¼Ó¹ÝÀÀ
  • supporting reaction
    ÁöÁö¹ÝÀÀ
  • supravital reaction
    ÃÊ»ýü¹ÝÀÀ
  • systemic reaction
    Àü½Å¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • psychoneurotic reaction
    Á¤½Å½Å°æÁõ¹ÝÀÀ
  • psychotic depressive reaction
    Á¤½Å¿ì¿ï¹ÝÀÀ
  • pyrogenic reaction
    ¹ß¿­¹ÝÀÀ
  • reaction period
    ¹ÝÀÀ±â
  • quellung reaction
    ÆØÃ¢¹ÝÀÀ
  • reaction
    ¹ÝÀÀ
  • rate limiting reaction
    ¼ÓµµÁ¦ÇѹÝÀÀ
  • reaction sequence
    ¹ÝÀÀ¼ø¼­
  • reaction substance
    ¹ÝÀÀ¹°Áú
  • reaction threshold
    ¹ÝÀÀ¹®Åΰª, ¹ÝÀÀ¿ªÄ¡
  • reaction time
    ¹ÝÀÀ½Ã°£
  • reaction velocity
    ¹ÝÀÀ¼Óµµ
  • recurrent reaction
    Àç¹ß¹ÝÀÀ
  • red reaction
    ¹ßÀûÀÛ¿ë
  • reflex like reaction
    ¹Ý»ç¸ð¾ç¹ÝÀÀ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • hyperkinetic reaction
    °ú´Ù¿îµ¿ ¹ÝÀÀ
  • hypersensitive reaction
    °ú¹Î¼º ¹ÝÀÀ(ΦÚÂàõÚãëë).
  • hypersensitivity reaction
    °ú¹Î¹ÝÀÀ
  • hypnic reaction
    ¼ö¸é¹ÝÀÀ(¡­Úãëë).
  • hypnic reaction
    ¼ö¸é ¹ÝÀÀ(â²ØùÚãëë)
  • hysteric reaction
    È÷½ºÅ׸®¼º ¹ÝÀÀ
  • hysteric reaction
    È÷½ºÅ׸®¼º ¹ÝÀÀ.
  • id reaction
    Id ¹ÝÀÀ
  • immune adherence reaction
    ¸é¿ªºÎÂø¹ÝÀÀ.
  • immune reaction
    ¸é¿ª¹ÝÀÀ.
  • immunologic reaction
    ¸é¿ª¹ÝÀÀ
  • immunological reaction
    ¸é¿ª¹ÝÀÀ.
  • immunoprecipitin reaction
    ¸é¿ªÄ§°­¹ÝÀÀ
  • indirect immunofluorescence reaction
    °£Á¢¸é¿ªÇü±¤¹ÝÀÀ.
  • indole reaction
    Àε¹¹ÝÀÀ.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
PLR pupillary light reflex
PLV partial liquid ventilation; poliomyelitis live vaccine; panleukopenia virus; phenylalanine, lysine, ...
PMLE polymorphous light eruption
QLS Quality of Life Scale; quasielastic light-scattering spectroscopy
UVL ultraviolet light
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
MLC(20) myosin light chain
MLC-2v myosin light chain 2
MLC kinase myosin light chain kinase
MLCKase myosin light chain kinase
PLS perpendicular light scatter
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
id reaction An allergic manifestation of candidiasis, the dermatophytoses, and other mycoses characterised by itching, vesicular lesions that appear in response to circulating antigens at sites that are often far distant from the primary fungal lesion itself.
See: dermatophytid, -id.
(05 Mar 2000)
dystonic reaction <pharmacology> Prolonged muscle contractions that may cause twisting and repetitive movements or abnormal posture. May occur in the form of rhythmic jerks. Can be seen as a side effect from antipsychotic medications and drugs used in the treatment of Parkinson's disease.
(27 Sep 1997)
immediate hypersensitivity reaction An immune response mediated by antibody, usually IgE, which occurs within minutes after a second encounter with an antigen, resulting in the release of histamine and subsequent swelling and vasodilation.
(05 Mar 2000)
immediate reaction Local or generalised response that begins within a few minutes to about an hour after exposure to an antigen to which the individual has been sensitised.
See: skin test, wheal-and-erythema reaction.
Synonym: early reaction.
(05 Mar 2000)
immune adherence reaction A method for the detection of very small quantities of antibody in which the antigen-antibody-complement complex adheres to indicator cells, usually primate erythrocytes or nonprimate blood platelets. The reaction is dependent on the number of bound c3 molecules on the c3b receptor sites of the indicator cell.
(12 Dec 1998)
immune reaction Antigen-antibody reaction indicating a certain degree of resistance, usually in reference to the 36-to 48-hour reaction in vaccination against smallpox; because the degree of resistance indicated by the reaction is not true immunity and may disappear relatively rapidly there is a tendency to refer to the immune reaction as an allergic reaction.
(05 Mar 2000)
incompatible blood transfusion reaction A syndrome due to intravascular haemolysis of transfused blood by serum antibodies of the recipient, which react with an antigen of the donor red cells; characterised by chills, fever (often with urticaria), backache or muscle cramps, haemoglobinaemia, haemoglobinuria, and oliguria, which may result in acute renal failure, DIC, and death.
(05 Mar 2000)
Quellung reaction Swelling of the capsule surrounding a bacterium as a result of interaction with anticapsular antibody, consequently the capsule becomes more refractile and conspicuous.
(18 Nov 1997)
indirect pupillary reaction Contraction of the pupil of the fellow eye in consensus with the pupil of the illuminated eye.
Synonym: consensual light reflex, indirect pupillary reaction.
(05 Mar 2000)
insulin reaction A sudden uncontrolled decline in the blood sugar due to effects of insulin.
(27 Sep 1997)
intracutaneous reaction Intradermal reaction, a reaction following the injection of antigen into the skin of a sensitive subject, such as in the case of the tuberculin test.
(05 Mar 2000)
iodate reaction of epinephrine A reaction dependent upon the oxidation of epinephrine by iodine liberated from iodate, which is decomposed by the hormone; a faint pink colour results.
(05 Mar 2000)
iodine reaction of epinephrine A reaction resulting from the oxidation of the hormone, a faint pink colour appearing upon the addition of iodine.
(05 Mar 2000)
irreversible reaction A reaction or response by the tissues to a pathogenic agent characterised by a permanent pathologic change.
(05 Mar 2000)
oxidase reaction The formation of indol blue when a blood smear containing myeloid leukocytes is treated with a mixture of alpha-naphthol and p-dimethylaniline sulfate; the myeloid leukocytes contain an oxidase that catalyses this reaction, the lymphoid leukocytes do not, in bacteriology, a reaction that depends on the presence of certain oxidases in some bacteria that catalyze the transport of electrons between electron donors in the bacteria and an oxidation reduction dye, such as tetramethyl-p-phenylenediamine; the dye is reduced to a blue or black colour.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á